Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry varying levels of risk.

Prothena Corporation plc today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint (HR=0.915, p-value=0.7680). Based ...

Here's a recap of the week’s most important stories.

During the third quarter, the Lazard International Equity Advantage Portfolio underperformed the MSCI EAFE Index (net of fees ...

Ich bin damit einverstanden, dass mir die BurdaForward GmbH, St. Martin Straße 66, 81541 München, regelmäßig News zu den oben ausgewählten Themenbereichen per E-Mail zusendet. Ich bin ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...